Name change reflects transition towards potential commercial organization in 2027

Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026

enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to "enGene Therapeutics Inc." effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across several cohorts of high-risk non-muscle invasive bladder cancer (NMIBC), including a pivotal cohort in BCG-unresponsive NMIBC with carcinoma in situ (CIS).

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.